RALEIGH, N.C. (AP) - Salix Pharmaceuticals Ltd. said Wednesday that the Food and Drug Administration approved its drug Fulyzaq, which is designed to treat diarrhea in patients taking HIV and AIDS drugs. Its shares rose more than 5 percent in midday trading.
Salix said it plans to start marketing the drug in early 2013. The company said Fulyzaq could have up to five years of marketing exclusivity, meaning similar products won't be approved in that time.
The drug is designed to treat diarrhea in patients with HIV or AIDS who are on anti-retroviral therapy. Salix says many patients who are taking anti-retroviral drugs experience episodic or chronic diarrhea, which can lead to weight loss and affect compliance with the treatment.
Salix said Fulyzaq, or crofelemer, is the first FDA-approved botanical drug that is intended to be taken orally. The active ingredient in the drug is derived from the sap of a tree called Croton lechleri, and is commonly known as "dragon's blood" because of the red color of the sap. The ingredient is isolated and purified after the sap is extracted.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
While the roads were looking clearer Friday morning in the Albuquerque area, appearances can be deceiving
Today's top headlines with Matt Mauro and Elizabeth Alvarez. Weather with Meteorologist Kristen Van Dyke
In nearly seven decades spent fighting for freedom and equality, Nelson Mandela inspired and challenged the world to stand up for others. As word of Mandela's death spread, current and former presidents, athletes and entertainers, and …
Four and a half years after he went to prison, former state senate leader Manny Aragon is out.
A suspected meth kingpin the FBI thought might be hiding out in New Mexico has been captured.
The popular Capulin Snow Play Area near Sandia Peak will be closed for the second year in a row.